#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy Spain

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Italy Spain

  • Study on the Safety and Effects of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2-positive Metastatic Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Italy Poland Spain

  • Study of Pertuzumab and Trastuzumab for Patients with Solid Malignant Tumors from Previous Pertuzumab Trials

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy Portugal Spain

  • Study on the Effectiveness and Safety of Trastuzumab, Tucatinib, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study of Ipatasertib with Trastuzumab and Pertuzumab for Patients with Advanced HER2-Positive Breast Cancer and PIK3CA Mutation

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia Denmark France Germany Greece +7

  • Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy Portugal Spain

  • Study on Time Savings with Subcutaneous Pertuzumab and Trastuzumab for Patients with HER2-Positive Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium France Germany Hungary Italy Poland +2